Chorionic gonadotrophin

Generic Medicine Info
Indications and Dosage
Delayed puberty associated with hypogonadism in males
Adult: Male: 1,500 units twice weekly for at least 6 months.

Male infertility due to hypogonadotropic hypogonadism
Adult: 500-1,000 units 2-3 times weekly.

Anovulatory infertility
Adult: Single dose of 5000-10,000 u. Up to 3 repeated injections of up to 5000 u each may be given within the following 9 days to prevent corpus luteum insufficiency.
Hypersensitivity; precocious puberty, prostatic carcinoma or other androgenic dependent neoplasm. Pregnancy and lactation.
Special Precautions
Discontinue therapy if signs of precocious puberty are seen in patients treated for cryptorchidism. Patients with cardiac or renal disease, epilepsy, migraine or asthma.
Adverse Reactions
Headache, irritability, restlessness, depression, fatigue, oedema; precocious puberty, gynaecomastia; pain at Inj site; enlargement of preexisting ovarian cysts and possible rupture; arterial thromboembolism; shock; abdominal pain.
Potentially Fatal: Ovarian hyperstimulation syndrome (OHSS).
IM/Parenteral/SC: X
Description: Chorionic Gonadotrophin is a polypeptide hormone produced by the human placenta. It stimulates the production of gonadal steroid hormones by inducing interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone.
Absorption: Peak concentrations after 6 hrs (IM).
Distribution: Mainly in the gonads.
Excretion: Via the urine (10-12% of IM dose within 24 hrs). Elimination half-life: 6-11 hrs (initial phase), 23-38 hrs (terminal phase).
Store at 15-30°C.
MIMS Class
Trophic Hormones & Related Synthetic Drugs
Disclaimer: This information is independently developed by MIMS based on Chorionic gonadotrophin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in